This new mutation is called "the deletion of the NFKB1A gene."
Researchers already knew that a third of glioblastoma brain cancers were caused by a genetic mutation. The newly discovered mutation accounts for another 25 percent.
Clinical trials are already underway for new drugs to target the mutation.
The study is reported in the New England Journal of Medicine.